Interv Cardiol Clin. 2026 Oct;15(4):605-622. doi: 10.1016/j.iccl.2026.05.005. Epub 2026 Jul 21.
ABSTRACT
Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) has emerged as a key reintervention strategy for failed surgical bioprostheses. Meticulous preprocedural planning with computed tomography, fluoroscopy, and transesophageal echocardiography is essential for optimal outcomes. Emerging artificial intelligence-based technologies may help mitigate associated risks such as coronary obstruction and patient-prosthesis mismatch and assist with lifetime management planning for valvular heart disease. Transcatheter valve underexpansion can be addressed through bioprosthetic valve fracture in select cases. ViV-TAVR is likely to continue to grow in prevalence given an aging population, its minimally invasive nature compared to redo surgical aortic valve replacement, and its favorable safety profile.
PMID:42648863 | DOI:10.1016/j.iccl.2026.05.005